Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Webcasts|June 20, 2022

GMP Biomanufacturing solutions: Walk the halls of Getinge Applikon following a stainless steel Project

Author(s)Getinge

Monday June 20th, 2022 at 11am ET | 10am CT | 8am PT Getinge Applikon invites you to get a glimpse of a process for stainless steel bioreactor manufacturing and verification. Walk through the halls of our manufacturing facility and see how commercial scale stainless steel vessels take shape, get to know Getinge engineers, visit manufacturing stages, and hear how the experts collaborate to configure and fabricate a system for manufacturing.

Register Free: https://www.biopharminternational.com/bp_w/Applikon

Event Overview:

Commercial scale stainless steel bioreactors for GMP require modifications aligned to each specific process. Getinge, formerly Applikon Biotechnology, has been a trusted partner for commercial stainless steel systems for over 30 years. This webinar offers a window into how a typical stainless steel project proceeds through the Getinge Applikon manufacturing site in Delft NL.

  • Starting a project right; Sales transfer to the Project Manager
  • System design and associated technical drawings with Engineering
  • Assembly and verification on the production floor
  • Factory Acceptance Testing (FAT) with QC

Key Learning Objectives:

  • Hear the Engineers describe design specifications for a manufacturing stainless steel system
  • Learn about key considerations at each stage in a stainless steel project
  • See a system in progress in the manufacturing facility

Who Should Attend:

  • Biomanufacturing professionals and those curious about scale-up into stainless steel bioreactors

Speakers

Imko Gaastra
Product Manager
Getinge

Imko Gaastra is product manager for the bioreactor portfolio at Getinge, formerly Applikon Biotechnology, since November 2017. His main responsibility is the large-scale bioreactor line up. Imko has a Master’s degree in Molecular Life Sciences and graduated at the Wageningen University & Research in the Netherlands in 2016.

Register Free: https://www.biopharminternational.com/bp_w/Applikon

​

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more